Hercules Capital, a specialty financing provider to venture, growth and established stage companies backed by venture capital and select private equity firms, has originated more than $1 billion year-to-date in annual total debt and equity commitments for the fourth consecutive year.
The U.S. Small Business Administration issued a “green light” or “go forth” letter inviting Hercules Capital to finalize its application process to obtain a license to form and operate a third small business investment company subsidiary.
Tricida has entered into an amendment to its existing debt facility with Hercules Capital. The amendment increases the total amount available under the debt facility to up to $200 million and extends the maturity of the loans thereunder. Tricida originally entered into a $100 million debt facility with Hercules Capital in February 2018.
Hercules Capital CEO Manuel Henriquez has voluntarily stepped aside as the firm’s chairman and CEO. According to Bloomberg, the news comes in the wake of Henriquez’s indictment by federal authorities because of his alleged involvement in the college admissions cheating scandal.
Hercules Capital closed a term loan of up to $75 million for Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.
Cell-based medicine developer Mesoblast entered into a $75 million non-dilutive, four-year credit facility with specialty finance company Hercules Capital.
Sorrento Therapeutics, a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases, entered into a loan and security agreement with Hercules Capital for up to $75 million.